Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study

Inger Johanne Zwicky Eide, Harald Grut, Åslaug Helland, Simon Ekman, Jens Benn Sørensen, Karin Holmskov Hansen, Bjørn Henning Grønberg, Saulius Cicenas, Jussi Pekka Koivunen, Anders Mellemgaard & Odd Terje Brustugun
Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect of osimertinib on brain metastases in both T790M-positive and -negative patients. The TREM-study was an investigator-initiated phase II, single-arm, multi-institutional clinical trial conducted in Northern Europe. Patients with resistance to prior EGFR-TKIs received osimertinib until radiological progression, unacceptable toxicity or death. Baseline brain scans were performed in...
1 citation reported since publication in 2021.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.